Skip to main content
Transgene logo

Transgene — Investor Relations & Filings

Ticker · TNG ISIN · FR0005175080 LEI · 969500PDJW8N0FSGGK69 PA Professional, scientific and technical activities
Open in API
Filings indexed 800 across all filing types
Latest filing 2026-05-26 Regulatory Filings
Country FR France
Listing PA TNG

About Transgene

https://www.transgene.fr/en/

Transgene is a clinical-stage biotechnology company that designs and develops immunotherapies for the treatment of cancer. The company's strategy is based on two proprietary technology platforms. The myvac® platform is used to create individualized neoantigen therapeutic vaccines, such as its clinical candidate TG4050, which leverages advanced genetic engineering and artificial intelligence. The invir.IO® platform is dedicated to developing innovative, multifunctional oncolytic viruses engineered to directly destroy cancer cells and modulate the tumor microenvironment, thereby enhancing the patient's immune response against the tumor.

Recent filings

Filing Released Lang Actions
Transgene présente des résultats précliniques avec TG-MVA, un nouveau vaccin prophylactique contre la variole du singe (mpox), au Congrès mondial sur les maladies infectieuses
Regulatory Filings Classification · 90% confidence The document is a press release announcing preclinical vaccine results and an upcoming oral presentation at a scientific congress. It contains no financial statements, no regulatory certification, no voting results, nor any of the specified specialized filings (e.g., Annual Report, Earnings Release, M&A, etc.). It is not publishing a formal report but rather making a corporate announcement. Therefore, it falls into the general fallback category “Regulatory Filings (RNS).”
2026-05-26 French
Transgene to Present Preclinical Data on Novel TG-MVA Prophylactic Vaccine Against mpox at the World Congress on Infectious Diseases
Regulatory Filings Classification · 80% confidence The document is a corporate press release announcing an upcoming oral presentation of preclinical vaccine data at a scientific congress. It contains no financial results, no reference to regulatory filings like annual or interim reports, no voting, board changes, or capital-raising, and does not provide substantive financial data. It does not constitute an investor presentation or a proxy statement, nor does it announce a published report. As it does not fit any other specific category, it falls into the miscellaneous Regulatory Filings category (RNS).
2026-05-26 English
Assemblée Générale Mixte de Transgene du 22 mai 2026
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a press release detailing the outcome of Transgene’s Mixed Annual General Meeting (Assemblée Générale Mixte) held on May 22, 2026. It summarizes the resolutions passed, the renewal and appointment of board members, and refers to vote results. This falls squarely under “Declaration of Voting Results & Voting Rights Announcements.”
2026-05-22 French
Transgene’s Combined General Meeting of May 22, 2026
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is a press release summarizing the outcome of Transgene’s Combined General Meeting (ordinary and extraordinary), including the approval of resolutions, renewal of directors’ mandates, and nomination of new independent directors. It clearly reports the official voting outcomes at a shareholder meeting. This matches the “Declaration of Voting Results” category.
2026-05-22 English
Mise à disposition des documents préparatoires à l'Assemblée générale du 22 mai 2026
AGM Information Classification · 95% confidence The document is a press release announcing the availability of preparatory documents for the Annual General Meeting (AGM) scheduled for May 22, 2026. It includes details about the meeting agenda, resolutions, participation, and voting procedures. It does not contain the actual AGM materials or minutes but rather informs stakeholders where and how to access them. The document is relatively short (5155 characters) and serves as an announcement rather than the AGM materials themselves. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the AGM or announcements related to it.
2026-05-04 French
Availability of Preparatory Documents for the Combined General Meeting of May 22, 2026
Report Publication Announcement Classification · 95% confidence The document is a press release announcing the availability of preparatory documents for a Combined General Meeting scheduled for May 22, 2026. It includes details about the notice of meeting, agenda, draft resolutions, and how shareholders can attend and vote. There is no actual report or financial data included, only an announcement about the meeting and where to find related documents. The document length is 4688 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this fits the category of a Report Publication Announcement (RPA) rather than the actual AGM materials or other report types.
2026-05-04 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.